Cardiff University researchers have been awarded a £2.3 million Development Pathway Funding Scheme grant from the Medical Research Council (MRC) to advance the development of an innovative approach to treating acute myeloid leukaemia.The award will f
Stock photo of doctor and patient A NEW clinical trial could lead to less toxic treatment for blood cancer. Cardiff and Vale University Health Board is implementing a new clinical trial which will give blood cancer patients access to a promising, active lower intensity treatment option. The VICTOR clinical trial, which is funded by Cancer Research UK and led by Dr Richard Dillon from Guy’s Hospital in London, will examine the efficacy of venetoclax-based treatment in treating certain groups of older patients with acute myeloid leukaemia (AML). If found to be effective, the treatment could spare future patients some of the more toxic effects of traditional intensive chemotherapy.